Sarah Tomassetti
Hematology & Oncology · Torrance, CANPI 1003159427
Payments from drug & device makers
Across 204 payments — averaging $14,579 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1.8M
- Merck$563K
- Genentech, Inc.$193K
- Seagen Inc.$164K
- Sanofi US Services Inc.$103K
- Rigel Pharmaceuticals, Inc.$72K
- plus $106K from 27 others
Across 8 payments — averaging $3418.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rigel Pharmaceuticals, Inc.$25K
- Novartis$2K
What the payments were for
- Consulting fees$9,49174%
- Speaking & faculty fees$1,46311%
- Food & beverage$1,74514%
- Education$1061%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 25 | $1,772,070 |
| Merck | 17 | $563,137 |
| Genentech, Inc. | 15 | $193,450 |
| Seagen Inc. | 12 | $164,404 |
| Sanofi US Services Inc. | 31 | $102,536 |
| Rigel Pharmaceuticals, Inc. | 9 | $72,286 |
| Sanofi | 10 | $57,794 |
| Beigene, Ltd. | 17 | $42,604 |
| AstraZeneca(2 entities) | 7 | $2,681 |
| Taiho Oncology, Inc. | 1 | $1,560 |
| Genentech USA, Inc. | 14 | $328 |
| Pfizer | 11 | $170 |
| Lilly USA, LLC | 4 | $150 |
| Incyte Corporation | 4 | $104 |
| Bristol Myers Squibb | 3 | $95 |
| E.r. Squibb & Sons, L.L.C. | 6 | $80 |
| GSK | 1 | $67 |
| Amgen | 2 | $62 |
| EMD Serono, Inc. | 1 | $50 |
| Exelixis Inc. | 1 | $41 |
| Johnson & Johnson | 1 | $40 |
| Blueprint Medicines Corporation | 1 | $36 |
| ADC Therapeutics America, Inc. | 1 | $33 |
| Gilead | 1 | $30 |
| Karyopharm Therapeutics Inc. | 1 | $29 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $28 |
| Servier Pharmaceuticals LLC | 1 | $25 |
| Pharmacosmos Therapeutics Inc. | 1 | $24 |
| Eisai Inc. | 1 | $23 |
| Stemline Therapeutics Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Mirati Therapeutics, Inc. | 1 | $20 |
| Adaptive Biotechnologies Corporation | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,974,016 in reported general payments places this provider in the 90th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Torrance
- David ChanTorrance$8.2M
- Alain AlgaziSan Francisco$119.2M
- David BerzLos Angeles$43.3M
- Jonathan GoldmanSanta Monica$35.7M
- Omid HamidSanta Monica$23.7M
- Nicholas McAndrewLos Angeles$22.9M
- Aditya BardiaSanta Monica$22.1M
- Joseph TuscanoSacramento$20.4M
- Zev WainbergSanta Monica$19.3M
- Caitlin CostelloSan Diego$16.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.